<DOC>
	<DOC>NCT01078168</DOC>
	<brief_summary>The trials investigates the changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease.The present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin in AD patients should be proven.</brief_summary>
	<brief_title>Alzheimer`s Disease Acitretin Medication</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>mild to moderate AD (NINCDSADRDA criteria) MMSE: 2714 points Geriatric Depression Scale ≤ 14 hereditary cognitive impairment known history of brain injuries Insufficient German language skills actual treatment with other potential disease modifying drugs of AD multimorbidity or significant organ (esp. liver or renal) dysfunction evidence of NonAD neurodegenerative disorder (e.g. Parkinson) contraindication to acitretin such as osteoporosis, hypoalbuminaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Alzheimer`s Disease</keyword>
</DOC>